Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | PRKCA | P17252 | 3/20 | 0.33 |
| ▸ | TAS2R46 | P59540 | 2/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7747592 | 1.00 | CA1 (0.43) | CA1CA9TSHRPOLBCYP1A2 | |
| SCHEMBL10963251 | 0.87 | TSHR (0.36) | CA1CA9TSHRPOLBTAS2R46 | |
| SCHEMBL4093121 | 0.82 | CA1 (0.38) | CA1CA9POLBCYP1A2PRKCA | |
| SCHEMBL75437 | 0.82 | CA1 (0.38) | CA1CA9POLBCYP1A2PRKCA | |
| SCHEMBL5170309 | 0.82 | CA1 (0.40) | CA1CA9TSHRCYP1A2PRKCA | |
| SCHEMBL5171201 | 0.82 | CA1 (0.40) | CA1CA9TSHRCYP1A2PRKCA | |
| SCHEMBL447330 | 0.82 | CA1 (0.40) | CA1CA9TSHRCYP1A2PRKCA | |
| SCHEMBL9041353 | 0.80 | CA1 (0.39) | CA1CA9CYP1A2PRKCA | |
| SCHEMBL10626844 | 0.80 | CA1 (0.39) | CA1CA9TSHRCYP1A2PRKCA | |
| SCHEMBL10070922 | 0.79 | CA1 (0.39) | CA1CA9CYP1A2PRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110372642-B | Method for treating homoserine-based compounds | CJ第一制糖株式会社 | 2023-04-07 | — | — | CN | claimed |
| EP-3130586-B1 | PROCESS FOR TREATING HOMOSERINE-BASED COMPOUND | CJ CHEILJEDANG CORP (KR) | 2019-10-23 | — | — | EP | claimed |
| US-10100026-B2 | Process for treating homoserine-based compound | CJ CHEILJEDANG CORPORATION (KR) | 2018-10-16 | — | — | US | claimed |
| EP-3130586-A1 | PROCESS FOR TREATING HOMOSERINE-BASED COMPOUND | Cj Cheiljedang Corporation (KR) | 2017-02-15 | — | — | EP | claimed |
| US-20170037019-A1 | PROCESS FOR TREATING HOMOSERINE-BASED COMPOUND | CJ CHEILJEDANG CORPORATION (KR) | 2017-02-09 | — | — | US | claimed |
| EP-1532146-B1 | A METHOD OF PREPARING ENANTIOMERS OF INDOLE-2,3-DIONE-3-OXIME DERIVATIVES | NEUROSEARCH AS (DK) | 2006-03-01 | — | — | EP | claimed |
| US-20050209355-A1 | [Novel Reactions and the Products of Such Reactions] | ROITMAN LIPA L | 2005-09-22 | — | — | US | claimed |
| CN-110372642-B | Method for treating homoserine-based compounds | CJ第一制糖株式会社 | 2023-04-07 | — | — | CN | disclosed |
| EP-3130586-B1 | PROCESS FOR TREATING HOMOSERINE-BASED COMPOUND | CJ CHEILJEDANG CORP (KR) | 2019-10-23 | — | — | EP | disclosed |
| US-10100026-B2 | Process for treating homoserine-based compound | CJ CHEILJEDANG CORPORATION (KR) | 2018-10-16 | — | — | US | disclosed |
| US-20180120706-A1 | PATTERN FORMING METHOD, LAMINATE, AND RESIST COMPOSITION FOR ORGANIC SOLVENT DEVELOPMENT | FUJIFILM CORPORATION (JP) | 2018-05-03 | — | — | US | disclosed |
| EP-3130586-A1 | PROCESS FOR TREATING HOMOSERINE-BASED COMPOUND | Cj Cheiljedang Corporation (KR) | 2017-02-15 | — | — | EP | disclosed |
| US-20170037019-A1 | PROCESS FOR TREATING HOMOSERINE-BASED COMPOUND | CJ CHEILJEDANG CORPORATION (KR) | 2017-02-09 | — | — | US | disclosed |
| WO-2007035066-A1 | THE METHOD OF MAKING OPTICALLY ACTIVE 3-ACYLOXY-GAMMA-BUTYROLACTONE AND OPTICALLY ACTIVE 3-HYDROXY-GAMMA-BUTYROLACTONE BY ENZYMATIC METHOD | ENZYTECH, LTD. (KR) | 2007-03-29 | — | — | WO | disclosed |
| US-20050209355-A1 | [Novel Reactions and the Products of Such Reactions] | ROITMAN LIPA L | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037019-A1 | PROCESS FOR TREATING HOMOSERINE-BASED COMPOUND | CBS, CTH, DHPS | CA1 4382/4885CA9 3963/4885TSHR 4048/4885 |
| US-10100026-B2 | Process for treating homoserine-based compound | CBS, CTH, DHPS | CA1 4382/4885CA9 3963/4885TSHR 4048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.